Search Results - receptor

43 Results

Sort By:

METHODS AND COMPOSITIONS IN PROGRAMMABLE RECEPTOR FOR ANTIGEN DETECTION AND CUSTOMIZED CELL RESPONSES

METHODS AND COMPOSITIONS IN PROGRAMMABLE RECEPTOR FOR ANTIGEN DETECTION AND CUSTOMIZED CELL RESPONSES Researchers at Stanford have developed new methods to create programmable synthetic receptors (PAGER). The advent of programmable synthetic receptors represents a new era in cellular therapies and in biomedical science. There are currently tens...

Published: 12/5/2023 | Inventor(s): Nicholas Kalogriopoulos, Alice Ting, Matthew Ravalin, Reika Tei

Keywords(s): Antibody, Fusion Protein, Receptor

Category(s): Technology Classifications > Biology

CORONAVIRUS NEUTRALIZING COMPOSITIONS AND ASSOCIATED METHODS

CORONAVIRUS NEUTRALIZING COMPOSITIONS AND ASSOCIATED METHODS Researchers at CZ Biohub SF and Stanford have developed unique fusion proteins that have broad therapeutic benefits for the treatment of infection by existing and future coronaviruses. Coronaviruses cause human illness ranging from the common cold to more severe diseases. They are large,...

Published: 12/5/2024 | Inventor(s): Payton Weidenbacher, Peter Kim, Eric Waltari

Keywords(s): Antibody, Broad-Spectrum, Coronavirus, Fusion Protein, Highly-Conserved, Inhibitor, Neutralizing, Receptor, Variant

Category(s): Technology Classifications > Biology

MEASUREMENT OF AFUCOSYLATED IgG Fc GLYCANS TO PREDICT RISK OF SEVERE COVID-19 DISEASE

MEASUREMENT OF AFUCOSYLATED IgG Fc GLYCANS TO PREDICT RISK OF SEVERE COVID-19 DISEASE Researchers at Stanford have developed a method for identifying a subject that is at risk of progression to clinically significant COVID-19 infection or disease. A minority of individuals infected with SARS-CoV-2 mount an extreme inflammatory response that...

Published: 3/17/2023 | Inventor(s): Taia Wang

Keywords(s): Afucosylation, Antibody, COVID-19, Glycoform, Glycosylation, IgG, Non-Neutralizing, Receptor, Symptom, Vaccine

Category(s): Technology Classifications > Biology

Stable, High-Yield Production of DT390-EGF Fusion Protein for Treatment of EGF-Receptor-Positive Cancers

This invention relates to the stable and high-yield production of a high-potency toxin protein called DT390-EGF. This toxin was developed for the treatment of EGF-receptor-positive cancers, including bladder cancer. Initial methods for synthesizing DT390-EGF relied on the use of E. coli. However, the production in E. coli was difficult to prepare and...

Published: 10/28/2024 | Inventor(s): Jung-hee Woo, David Neville, Arthur Frankel, Andrew Thorburn, Michael Glode, Thomas Flaig

Keywords(s): cancers, DT390-EGF, EGF, Fusion, POSITIVE, Protein, RECEPTOR, treatment, VCXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Oncology, Application > Therapeutics

Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction

This technology includes a chemical series, including the NCGC00538279 compound, that selectively activates the GHSR1a G-protein pathway for calcium mobilization while only partially activating the beta-arrestin-2 translocation pathway. The resulting chemical series may be therapeutically valuable for addictive disorders. Activation of the GHSR1a G-protein...

Published: 10/28/2024 | Inventor(s): Noel Southall, Marc Ferrer-Alegre, Daniel Jansen, Mark Henderson, Xin Hu, David Kim, Juan Marugan

Keywords(s): ADDICTION, Chemical, FOOD, Funtionally, Ghrelin, LIGAND, NCG00538279, Novel, RECEPTOR, SELECTIVE, treatment, VEXXXX, VGXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Neurology, Application > Therapeutics, TherapeuticArea > Endocrinology, Application > Research Materials

Potential New Drugs for Treating or Preventing Pruritus

NIH scientists have identified new compositions that could potentially be used to treat or prevent pruritus (itchiness). The newly discovered compounds can block a newly identified itch pathway and might be effective for persistent itch caused by psoriasis, atopic dermatitis, renal failure, liver cirrhosis and chemotherapy. These compounds are different...

Published: 12/31/2024 | Inventor(s): Hans Solinski, James Inglese, Patricia Dranchak, Mark Hoon

Keywords(s): BLOCKAGE, IB6XXX, Itch, Listed LPM Vepa as of 4/15/2015, Nppb, Npr1, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, Sensation, TRANSMITTER, treatment, VOXXXX, VPXXXX, WKXXXX, XHXXXX, YAXXXX, YBXXXX, YCXXXX

Category(s): TherapeuticArea > Reproductive Health, TherapeuticArea > Oncology, Application > Consumer Products, TherapeuticArea > Infectious Disease, ResearchProducts > Research Equipment, TherapeuticArea > Ophthalmology, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, TherapeuticArea > Cardiology

Hybridoma Cell Line H9.2B8 Producing Monoclonal Anti-mouse CD51 (Vitronectin receptor, alpha chain) Antibody

A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD51 (vitronectin receptor, alpha chain) (clone H9.2B8) as described in J Exp Med. 1989 Jun 1;169(6):2173-90 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

Published: 10/28/2024 | Inventor(s): Ethan Shevach

Keywords(s): AC5XXX, Against, ALPHA, antibodies, ANTIGENS, Cell, Chain, Clone:, H9.2B8, Hamster, Hybridoma, Listed LPM Nguyen-Antczak as of 4/15/2015, Mab, Mouse, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, Surface, Vitronectin, WIXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials

Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA

A plasmid encodes human CC chemokine receptor CX3CR1/CMKBRL1 as described in DNA Cell Biol. 1995 Aug;14(8):673-80, and developed in the laboratory of Philip M. Murphy at the National Institute of Allergy and Infectious Diseases.

Published: 10/28/2024 | Inventor(s): Philip Murphy

Keywords(s): cc, CC-CMKBRL1, cDNA, Chemokine, Human, PLASMID, RECEPTOR, RM, WIXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials

CXCR1 - Human IL-8 Receptor cDNA

A plasmid encodes human interleukin-8 (IL-8) receptor CXCR1. IL-8 is a chemo-attractant cytokine that attracts and activates neutrophils in inflammatory regions.

Published: 10/28/2024 | Inventor(s): Sunil Ahuja, Philip Murphy

Keywords(s): CB3AXX, CC1XXX, cDNA, CXCRI, Hu, Human, IL-8, IL-8A, Listed LPM Ano as of 4/15/2015, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, Subtype, WIXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Application > Research Materials

Human CCR2 cDNA

A plasmid encodes human C-C chemokine receptor type 2 (CCR2). CCR2 play important roles in the recruitment of monocytes/macrophages and T cells.

Published: 10/28/2024 | Inventor(s): Sunil Ahuja, Christophe Combadiere, James Pease, Philip Murphy

Keywords(s): cc, CCR2, cDNA, Cell, Chemokine, Cloning, EOSINOPHIL, Expression, FUNCTIONAL, Human, Including, line., Listed LPM Ano as of 4/15/2015, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, WIXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials

1 2 3 4 5